4.7 Article

Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies

Journal

SCIENTIFIC REPORTS
Volume 6, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/srep24402

Keywords

-

Funding

  1. Sanofi Pasteur
  2. Ghent University Special Research Fund [BOF12/GOA/014]
  3. Fonds voor Wetenschappelijk Onderzoek Vlaanderen research projects [G052412N, G043515N]
  4. Belgian Federal Sciences Administration Project BELVIR [p7/45]
  5. FWO postdoctoral fellowship
  6. Fonds voor Wetenschappelijk Onderzoek [G054108N10]
  7. ERC Consolidator grant (GlycoTarget)
  8. Methusalem grant from Ghent University [BOF09/01M00709]

Ask authors/readers for more resources

There is mounting evidence that in the absence of neutralizing antibodies cross-reactive T cells provide protection against pandemic influenza viruses. Here, we compared protection and CD8+ T cell responses following challenge with H1N1 2009 pandemic and H3N2 viruses of mice that had been immunized with hemagglutinin (HA), neuraminidase (NA) and the extracellular domain of matrix protein 2 (M2e) fused to a virus-like particle (VLP). Mice were challenged a first time with a sublethal dose of H1N1 2009 pandemic virus and, four weeks later, challenged again with an H3N2 virus. Mice that had been vaccinated with HA, NA, NA + M2e-VLP and HA + NA + M2e-VLP were protected against homologous H1N1 virus challenge. Challenged NA and NA + M2e-VLP vaccinated mice mounted CD8+ T cell responses that correlated with protection against secondary H3N2 challenge. HA-vaccinated mice were fully protected against challenge with homologous H1N1 2009 virus, failed to mount cross-reactive CD8+ T cells and succumbed to the second challenge with heterologous H3N2 virus. In summary, NA- and M2e-based immunity can protect against challenge with (homologous) virus without compromising the induction of robust cross-reactive CD8+ T cell responses upon exposure to virus.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available